Pamorelin (Triptorelin)

Triptorelin, the active ingredient in Pamorelin, is a gonadotropin-releasing hormone (GnRH) agonist presented as a sterile powder for solution for injection use. It is used in the management of hormone‑dependent conditions such as prostate cancer, endometriosis and assisted‑reproductive protocols.

GNH USA supplies Pamorelin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology centres worldwide.

Pamorelin is a GnRH‑agonist that modulates the hypothalamic‑pituitary‑gonadal axis in several hormone‑dependent disease states. - Prostate cancer: provides androgen suppression to slow tumor progression. - Endometriosis: induces a hypo‑estrogenic state to reduce pelvic pain and lesion growth. - Assisted reproductive technology (ART) protocols: prevents premature luteinizing hormone surge during controlled ovarian stimulation. - Uterine fibroids: creates a low‑estrogen environment that can shrink fibroid size and lessen bleeding. - Precocious precocious puberty: delays further sexual development by suppressing gonadotropin release.

Side effects vary with treatment duration and patient characteristics.

Common Side Effects: - Hot flashes - Headache - Injection site pain or erythema - Fatigue - Mood changes - Decreased libido

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) - Cardiovascular events such as myocardial infarction - Bone density loss leading to osteoporosis - Liver function abnormalities - Pituitary apoplexy (very rare) - Severe depression or suicidal ideation

When prescribing Pamorelin, clinicians should consider several safety aspects. - Cardiovascular assessment: evaluate history of heart disease before initiating therapy. - Bone health monitoring: periodic bone mineral density scans are advised for long‑term use. - Hormone‑dependent tumor surveillance: continue regular oncologic assessments. - Pregnancy and lactation: avoid use in women who are pregnant, planning pregnancy or breastfeeding. - Drug interactions: review concomitant medications for potential CYP‑related effects. - Store at ambient temperature: keep in original container, protect from moisture and light.

Triptorelin may interact with several drug classes; awareness helps prevent reduced efficacy or heightened toxicity.

Major Interactions (Avoid): - Combined androgen‑deprivation therapy (ADT) with other GnRH agonists or antagonists – risk of excessive hormone suppression.\nModerate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole) – may alter hormone levels. - Anticoagulants (warfarin) – increased bleeding risk at injection sites.\n- Steroid ​​​ ​  ​  ​ ​ ​ ​ ​ ​ ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​ ​ ​ ​  ​​ ​ ​  ​  ​  ​  ​  ​  ​  ​  ​ ​ ​  ​ ​​  ​  ​ ​  ​ ​  ​ ​​  ​  ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​​ - Hormone replacement therapy (estrogen or testosterone): may blunt the intended suppressive effect. - Antidepressants (SSRIs): monitor mood changes as triptorelin can affect emotional state. - Bisphosphonates: consider bone health strategy when long‑term therapy is planned.